Figure 4.

(A) Graphical representation for comparison of IC₅₀ EGFR (µM) of compounds 4a–c, 4e, 5, and erlotinib, (B) graphical representation for comparison of IC₅₀ PI3Kβ (µM) of compounds 4a–c, 4e, 5 LY294002. Both enzymes were performed using four-dose protocol. The data are expressed as mean ± SD (n = 3 experiments), statistical analysis was performed by two-way ANOVA followed by Tukey’s post hoc test with *significant at p > 0.05, **significant at p > 0.01, ***significant at p > 0.001, and ****significant at p > 0.0001 and ^nsno significance.